Real-World Use of Secukinumab Among Biologic-NaiVe and Biologic-Experienced Patients with Ankylosing Spondylitis in the United States

被引：0
|
作者：
Oelke, Kurt R. [1 ]
Garg, Rahul [2 ]
Li, Yunfeng [3 ]
Liu, Xing [4 ]
Zhou, Huanxue [4 ]
Park, Yujin [3 ]
机构：
[1] Rheumat Dis Ctr, Glendale, WI USA
[2] PRO Unltd Inc, E Hanover, NJ USA
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] KMK Consulting Inc, Morristown, NJ USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1524
引用
收藏
页数：2
相关论文
共 50 条
  • [41] TWELVE-MONTH FOLLOW UP OF IXEKIZUMAB IN THE BADBIR REGISTRY: BASELINE DEMOGRAPHICS, DRUG SURVIVAL AND EFFECTIVENESS IN BIOLOGIC-NAIVE VERSUS BIOLOGIC-EXPERIENCED PATIENTS WITH PSORIASIS
    Zaheri, S.
    Hughes, J.
    McKenzie, R.
    von Arx, L. B.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S246 - S246
  • [42] Secukinumab in United States Biologic-Naive Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study
    Nguyen, Tien
    Churchill, Melvin
    Levin, Robert
    Valenzuela, Guillermo
    Joseph, F. Merola .
    Alexis, Ogdie .
    Ana-Maria, Orbai .
    Scher, Jose U.
    Kavanaugh, Arthur
    Kianifard, Farid
    Rollins, Chauncy
    Calheiros, Renato
    Chambenoit, Olivier
    [J]. JOURNAL OF RHEUMATOLOGY, 2022, 49 (08) : 894 - 902
  • [43] Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisation
    Patel, H.
    Khalid, J. M.
    Shah, S.
    Shah, R.
    Berger, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S385 - S386
  • [44] Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naive and biologic exposed patients
    Cheesbrough, J.
    Quraishi, M. N.
    Sharma, N.
    Nassar, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I443 - I444
  • [45] REAL-WORLD EXPERIENCE OF USING TOFACITINIB IN ULCERATIVE COLITIS IN BIOLOGIC NAIVE AND BIOLOGIC EXPOSED PATIENTS
    Cheesbrough, Jonathan
    Sharma, Naveen
    Nassar, Islam
    Quraishi, Nabil
    [J]. GUT, 2022, 71 : A42 - A42
  • [46] Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naive and biologic exposed patients
    Cheesbrough, J.
    Quraishi, M. N.
    Sharma, N.
    Nassar, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I443 - I444
  • [47] COMPARISON OF REAL-WORLD TREATMENT OUTCOMES WITH INFLIXIMAB VERSUS VEDOLIZUMAB IN BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    Patel, Haridarshan
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S638 - S639
  • [48] Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA
    Andrew Blauvelt
    Nianwen Shi
    Najwa Somani
    Russel Burge
    Baojin Zhu
    Terri Ridenour
    Scott Kern
    Carolyn Lew
    Nicole Zimmerman
    Mwangi Murage
    [J]. Clinical Drug Investigation, 2023, 43 : 185 - 196
  • [49] REAL-WORLD COSTS IN BIOLOGIC-NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE
    Kaplan, D.
    Ung, B.
    Pelletier, C.
    Udeze, C.
    Tian, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S888 - S888
  • [50] Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease
    Patel, Haridarshan
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    [J]. CROHNS & COLITIS 360, 2019, 1 (02)
12345